Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash & Equivalents (2016 - 2026)

Corvus Pharmaceuticals' Cash & Equivalents history spans 12 years, with the latest figure at $40.1 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 702.2% to $40.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $40.1 million through Mar 2026, up 702.2% year-over-year, with the annual reading at $4.6 million for FY2025, 47.64% down from the prior year.
  • Cash & Equivalents came in at $40.1 million for Q1 2026, up from $4.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $40.1 million in Q1 2026 to a low of $2.9 million in Q3 2025.
  • The 5-year median for Cash & Equivalents is $12.6 million (2023), against an average of $14.7 million.
  • Year-over-year, Cash & Equivalents plummeted 79.26% in 2022 and then soared 702.2% in 2026.
  • Corvus Pharmaceuticals' Cash & Equivalents stood at $13.2 million in 2022, then dropped by 4.1% to $12.6 million in 2023, then plummeted by 30.74% to $8.7 million in 2024, then plummeted by 47.64% to $4.6 million in 2025, then surged by 776.35% to $40.1 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Cash & Equivalents are $40.1 million (Q1 2026), $4.6 million (Q4 2025), and $2.9 million (Q3 2025).